VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Ph 1/2 Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors June 30, 2026
FAILED TRIAL: Ph 3 SigVie-002/Be6A Lung-01 trial of sigvotatug vedotin in 2L+ NSCLC did not show a statistically significant OS improvement vs docetaxel June 30, 2026
Positive Ph 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma Announced June 30, 2026
FAILED TRIAL: Ph 2 DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet primary endpoint of PFS improvement June 30, 2026
FAILED TRIAL: Ph 3 TRIDENT trial of TTFields did not meet primary endpoint of significant OS increase in GBM patients when used early June 23, 2026
Positive Updated Results from RAMP 205 of Avutometinib, Defactinib and SOC chemo in 1L Metastatic Pancreatic Cancer Announced June 23, 2026
Multiple Complete Responses Reported After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer June 23, 2026
Ph 3 STELLAR-303 Trial of Zanzalintinib + Tecentriq in Metastatic CRC Patients didn’t meet the dual primary endpoint of OS improvement in the liver mets patients June 23, 2026
Updated clinical findings from GEP-NET patients treated with ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE) announced June 17, 2026
Ph 3 trial of Anbenitamab (KN026) + Docetaxel For Injection (Albumin-Bound) (HB1801) For 1L HER2+ve Advanced Breast Cancer Meets Primary Endpoint June 17, 2026
FAILED TRIAL: Ph 3 LAGOON trial of Zepzelca in patients with 2L SCLC did not meet primary endpoint of OS June 17, 2026
FAILED TRIAL: Ph 2 AMPLIFY-7P trial did not meet the pre-specified primary endpoint of DFS in the ITT adjuvant pancreatic cancer population June 17, 2026
Positive Mid-Year Interim Clinical Progress Reported from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer June 10, 2026
Lancet Oncology publishes results of Pivotal Ph 3 Significant DFS Improvement with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer June 10, 2026
NEJM publishes results from ASCERTAIN-V Ph 1/2 trial of decitabine-cedazuridine + venetoclax in 1L AML patients ineligible for intensive induction chemo June 10, 2026
IBI343 (arcotatug tavatecan) Met Primary Endpoint in Ph 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA June 10, 2026
Ph 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes did not meet predefined threshold to support further development June 2, 2026
Primary Endpoints Met in Final Analysis of Ph 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC June 2, 2026
Ph 3 Trial of Sacituzumab Tirumotecan (sac-TMT) vs Chemo as 1L Treatment for Advanced TNBC Met Primary Endpoint of PFS May 26, 2026
Ph 2 ARASEC Data Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic CSPC May 21, 2026
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic HSPC May 21, 2026
